Indivior PLC Indivior to Participate in Upcoming Investor Event

RNS Number : 2225N

Indivior PLC

22 November 2024

 

 

 

Indivior To Participate in Upcoming Investor Event

Slough, UK, and Richmond, VA, November 22, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor event:

 

·    Piper Sandler 36^th Annual Healthcare Conference - New York City, NY

 

Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 3^rd.  Mark Crossley will also participate in a fireside discussion on Tuesday, December 3^rd at 10:00 a.m. US ET.  Interested investors should contact their Piper Sandler representative to schedule a meeting.  The fireside chat will be publicly available and can be viewed using the following weblink:

 

Webcast Link

 

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: [phone] or [e-mail]

 

Tim Owens

Director, Investor Relations

Tel: [phone] or [e-mail]

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKDBPABDDODB